Current Affiliation Organization 【 display / non-display 】

Current Affiliation Organization 【 display / non-display 】

External Career 【 display / non-display 】

External Career 【 display / non-display 】

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohort.

  Saito R, Taoka R, Miki J, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Sazuka T, Kato M, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kinoshita H, Japan Urological Oncology Group

  International journal of clinical oncology     2025.07 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article

    DOI
  • Search related information
    PubMed

• Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective study.

  Sazuka T, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Sawada A, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Ichikawa T, Japan Urological Oncology Group

  International journal of clinical oncology ( International Journal of Clinical Oncology )  30 ( 7 ) 1417 - 1425   2025.07 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article

    DOI
  • Search related information
    PubMed

• Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective study(タイトル和訳中)

  Sazuka Tomokazu, Taoka Rikiya, Miki Jun, Saito Ryoichi, Fukuokaya Wataru, Matsui Yoshiyuki, Hatakeyama Shingo, Kawahara Takashi, Matsuda Ayumu, Kawai Taketo, Kato Minoru, Sano Takeshi, Urabe Fumihiko, Kashima Soki, Naito Hirohito, Murakami Yoji, Miyake Makito, Daizumoto Kei, Matsushita Yuto, Hayashi Takuji, Inokuchi Junichi, Sugino Yusuke, Shiga Kenichiro, Yamaguchi Noriya, Yamamoto Shingo, Yasue Keiji, Abe Takashige, Nakanishi Shotaro, Hashine Katsuyoshi, Sawada Atsuro, Nishihara Kiyoaki, Matsumoto Hiroaki, Tatarano Shuichi, Wada Koichiro, Sekito Sho, Maruyama Ryo, Nishiyama Naotaka, Nishiyama Hiroyuki, Kitamura Hiroshi, Ichikawa Tomohiko, the Japan Urological Oncology Group

  International Journal of Clinical Oncology ( シュプリンガー・ジャパン(株) )  30 ( 7 ) 1417 - 1425   2025.07 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

• Current Evidences and Future Perspectives in the Management of Metastatic Non-Clear Cell Renal Cell Carcinoma.

  Nakanishi S, Inokuchi J

  International journal of urology : official journal of the Japanese Urological Association ( International Journal of Urology )    2025.06 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article

    DOI
  • Search related information
    PubMed

• Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy

  Hatakeyama, S; Taoka, R; Miki, J; Saito, R; Fukuokaya, W; Matsui, Y; Kawahara, T; Matsuda, A; Kawai, T; Kato, M; Sazuka, T; Sano, T; Urabe, F; Kashima, S; Naito, H; Murakami, Y; Miyake, M; Daizumoto, K; Matsushita, Y; Hayashi, T; Inokuchi, J; Sugino, Y; Shiga, K; Yamaguchi, N; Taguchi, M; Yasue, K; Abe, T; Nakanishi, S; Hashine, K; Fujii, M; Nishihara, K; Matsumoto, H; Tatarano, S; Wada, K; Sekito, S; Maruyama, R; Nishiyama, N; Nishiyama, H; Kitamura, H; Ohyama, C

  CANCER MEDICINE ( Cancer Medicine )  14 ( 9 ) e70782   2025.05 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article

    DOI
  • Search related information
    PubMed

display all >>

Other Papers 【 display / non-display 】

Other Papers 【 display / non-display 】

• CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC PAPILLARY RENAL CELL CARCINOMA: A JAPANESE MULTI-INSTITUTIONAL STUDY

  Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayakazu Nakazawa, Mototsugu Oya, Seiichiro Ozono, Seiji Naito, Tomohiko Asano

  JOURNAL OF UROLOGY   195 ( 4 ) E23 - E24   2016.04  [Refereed]

   

  DOI

• 転移性乳頭状腎細胞癌と診断され中央病理診断で異なる腎癌に再分類された症例の臨床像―腎癌研究会多施設共同研究

  伊藤敬一, 三上修治, 立神勝則, 舛森直哉, 篠原信雄, 近藤恒徳, 仲西昌太郎, 長嶋洋治, 江藤正俊, 神波大己, 黒田直人, 冨田善彦, 松山豪泰, 大西哲郎, 津島知靖, 中澤速和, 大家基嗣, 大園誠一郎, 内藤誠二, 浅野友彦

  日本癌治療学会学術集会(Web)   54th   ROMBUNNO.MS6‐1 (WEB ONLY) - 1   2016

   

  J-GLOBAL

Presentations 【 display / non-display 】

Presentations 【 display / non-display 】

• 精巣腫瘍フォーラムの症例から学ぶ進行性精巣腫瘍治療　横紋筋肉腫への悪性転化を認めたpT2奇形種の1例(A case of pT2 teratoma with somatic-type malignancy as rhabdomyosarcoma)

  Nakanishi Shotaro, Tasaki Shinsuke, Arasaki Jyunichi, Yoshioka Takuya, Yasuda Sou, Matsuo Tomomasa, Takaesu Dai, Shimoji Akihisa, Izumi Keiichiro, Ashikari Asuka, Kimura Ryu, Saito Seiichi

  日本泌尿器科学会総会  1900.01  -  1900.01 

• 夜間頻尿に対する日中弾性ストッキング着用による効果の検証(Study of the effect of wearing elastic stockings during the day on nocturia)

  Ashikari Asuka, Miyazato Minoru, Koike Shin, Izumi Keiichiro, Kimura Ryu, Nakanishi Shotaro, Saito Seiichi

  日本泌尿器科学会総会  1900.01  -  1900.01 

• 去勢抵抗性前立腺癌患者血清におけるST3GAL2関連マーカーの発現(Expression of ST3GAL2-associated markers in sera of patients with castration-resistant prostate cancer)

  斎藤 誠一, 仲西 昌太郎, 須田 哲司, 田中 慧, 須川 愛, 宮田 康好

  日本泌尿器科学会総会  1900.01  -  1900.01 

• シアル酸転移酵素ST3GAL2は前立腺癌細胞株DU145にタキサン耐性を与える

  斎藤 誠一, 須田 哲司, 仲西 昌太郎, 小坂 威雄, 田中 慧, 島田 智子, 大家 基嗣

  日本癌治療学会学術集会抄録集  1900.01  -  1900.01 

• Efficacy of treatment for non-clear cell renal cell carcinoma(タイトル和訳中)

  Nakanishi Shotaro, Ekawa Ayumi, Nakanishi Yosuke, Nagamine Satsuki, Yashima Takuya, Tsunokawa Yoshiki, Kamiyama Masaru, Motonaga Aoi, Tanaka Kei, Yonamine Tomoko, Ashikari Asuka, Kimura Ryu, Inokuchi Junichi

  日本泌尿器科学会総会  1900.01  -  1900.01 

display all >>

Grant-in-Aid for Scientific Research 【 display / non-display 】

Grant-in-Aid for Scientific Research 【 display / non-display 】

• Grant-in-Aid for Young Scientists(B)

  Project Year: 2016.04  -  2019.03 

  Direct: 3,000,000 (YEN)  Overheads: 900,000 (YEN)  Total: 3,900,000 (YEN)

• Biological Role and Clinical Significance of Decreased Glycoprotein in Renal Cancer Serum

  Grant-in-Aid for Young Scientists(B)

  Project Year: 2016.04  -  2019.03 

  Investigator(s): Nakanishi Shotaro, Sugawa Ai 

  Direct: 3,000,000 (YEN)  Overheads: 3,900,000 (YEN)  Total: 900,000 (YEN)

  　View Summary

  The frequency of discovery of renal cancer is increasing, because of advances in diagnostic imaging techniques and an increase in screening opportunities. However, 25-30% of them are found in advanced cancers that have already metastasized at the time of discovery. Therefore, the search for renal cancer serum biomarkers is an essential task for early detection of renal cancer and that is improving the prognosis of renal cancer. Therefore, in this study, RCC-GP1 was used to examine its concentration in the serum of renal cancer patients and to explore its potential as a biomarker. Serum RCC-GP1 was significantly elevated in ccRCC patient sera compared to non-cc RCC and non cancer patients, suggesting the possibility of becoming a serum biomarker.

• Research on markers expressed in high-grade prostate cancer

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2016.04  -  2019.03 

  Investigator(s): Saito Seiichi, Miyata Yasuyoshi 

  Direct: 3,700,000 (YEN)  Overheads: 4,810,000 (YEN)  Total: 1,110,000 (YEN)

  　View Summary

  We identified molecules related to the malignant potential of prostate cancer in prostate cancer cell lines. Those included enzyme protein (prostate cancer glycoprotein-enzyme: PCGP-enz), glyprotein (GP) related to glycolysis (PCGP-glyco),GP related to blood pressre (PCGP-bp), GP related to stress response (PCGP-stress), GP related to ubiquitin (PCGP-ub), GP commonly expressed in triple negative breast cancer (PCGP-br), GP commonly expressed in lung cancer (PCGP-lc), GP expressed in endoplasmic reticulum (PCGP-er), etc. Among those PCGP-lc and PCGP-er were significantly associated with higher Gleason score and PCGP-er was also significantly related to T stage using radical prostatectomy specimens. We also found stage-specific embryonic antigen-4 (SSEA-4) was significantly associated with the malignant behavior of prostate cancer using clinical samples.

• Investigation of novel diagnostic biomarkers for prostate cancer based on RM2 antigen

  Grant-in-Aid for Young Scientists(B)

  Project Year: 2014.04  -  2017.03 

  Investigator(s): SUDA Tetsuji, SAITO Seiichi, NAKANISHI Shotaro, KANEYUKI Ayako, SUGAWA Ai 

  Direct: 2,900,000 (YEN)  Overheads: 3,770,000 (YEN)  Total: 870,000 (YEN)

  　View Summary

  Although RM2 antigen is a new histological marker for prostate cancer that may reflect the tumor stage, the target proteins carrying RM2 antigen are yet unclear. To identify the target proteins, we focused on amino acid sequence of the 50kDa protein that reacts strongly to RM2 antibody. Histological expression of several candidate proteins in prostate cancer was significantly associated with Gleason score. Among these, urine level of a candidate protein in the patients with prostate cancer decreased compared to those with benign prostate. These results suggested that these candidate proteins would be useful as a new histological or urine marker of prostate cancer.